Fellow of the Academy of Medical Sciences

DnaNudge and DAM Health Sign Partnership to Provide 90-Minute RT-PCR Covid-19 Tests in More Than 100 Clinics Across the UK and Internationally in the New Year

Retrieved on: 
Wednesday, December 15, 2021
Retail, Health, Other Retail, Infectious Diseases, General Health, Research, Science, Cloud, Health, Ranger, Hospital, Omicron, Crystal Palace F.C., Hypertension, PCR, MacRobert Award, Infection, DAM, RT-PCR, A Glimmer of Hope Foundation, FRS, Royal Academy of Arts, RT, Roosevelt, Imperial College London, COVID-19, Time, Mechanics, Scottish Rugby Union, Laboratory information management system, Engineering, DNA, Obesity, Eating, Coronavirus, Organic, Virtual reality, Virus, Cholesterol, The, New Year, RSV, DnaNudge, Royal, Diabetes, Football, Partnership, Technology, Genetic testing, Type 2 diabetes, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences

A further advantage of CovidNudge is confirmation of adequacy of the swab through a human RNAseP control, avoiding false negatives.

Key Points: 
  • A further advantage of CovidNudge is confirmation of adequacy of the swab through a human RNAseP control, avoiding false negatives.
  • It can multiplex up to 72 assays and detect every published Covid-19 gene and all known variants including Omicron.
  • The NudgeBox is a standalone instrument that provides the mechanics to drive the DnaCartridge and run RT-PCR tests.
  • DAM Health is the leading government-approved provider of in-clinic Covid-19 tests in the UK, employing over 1,000 employees across over 100 clinics in the UK and internationally.

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

Retrieved on: 
Tuesday, September 7, 2021

This placebo-controlled, randomized clinical trial is evaluating CAN-2409 treatment in combination with valacyclovir added to upfront standard of care external beam radiation therapy for patients with localized prostate cancer compared to standard of care radiation therapy alone.

Key Points: 
  • This placebo-controlled, randomized clinical trial is evaluating CAN-2409 treatment in combination with valacyclovir added to upfront standard of care external beam radiation therapy for patients with localized prostate cancer compared to standard of care radiation therapy alone.
  • We believe CAN-2409 could improve disease outcome in patients with prostate cancer, and we look forward to the results of this potentially registrational clinical trial in 2024.
  • Secondary endpoints include prostate cancer specific survival, overall survival, freedom from biochemical failure, patient reported health-related quality of life, and safety.
  • Currently, Candel is evaluating the effects of treatment with CAN-2409 in high-grade glioma, non-small cell lung cancer, pancreatic cancer, and prostate cancer in ongoing clinical trials.

Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors

Retrieved on: 
Tuesday, September 7, 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.
  • We are pleased to welcome Iain, a world-renowned leader in rheumatology and clinical immunology, to our Board of Directors, said Simba Gill, Ph.D., Chief Executive Officer of Evelo.
  • Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX, with systemic therapeutic effects.
  • Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer.